ALKS Q3 2021 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$294M+11.0% YoY

Gross Profit

$245M83.2% margin

Operating Income

-$20M-6.7% margin

Net Income

-$29M-9.9% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

-3.2%

Cash Flow

Operating Cash Flow

$83M

Free Cash Flow

$78M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$2.0B

Total Liabilities

$899M

Stockholders' Equity

$1.1B

Cash & Equivalents

$310M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$294M	$265M	+11.0%
Gross Profit	$245M	$222M	+10.2%
Operating Income	-$20M	-$11M	-84.3%
Net Income	-$29M	-$134,000	-21532.8%

Revenue Segments

Product

$158M50%

Vivitrol

$89M28%

Aristada And Aristada Initio

$69M22%